TITLE

Harsh Judgement for GSK's Avandia

PUB. DATE
August 2010
SOURCE
Pharmaceutical Representative;Aug2010, Vol. 40 Issue 8, p9
SOURCE TYPE
Periodical
DOC. TYPE
Article
ABSTRACT
The article reports that the Endocrinologic and Metabolic Drugs and Drug Safety and Risk Management Advisory Committees of Food & Drug Authority has decided to restrict or pull out the Avandia of GlaxoSmithKline from the market on July 13-14, 2010 in the U.S.
ACCESSION #
52817406

 

Related Articles

  • Food Safety Recalls: There's a Right Way. O'Neal, James // Defense Counsel Journal;Jul99, Vol. 66 Issue 3, p424 

    Presents an overview on food product recalls. Reasons for the increase in significant food recalls; Policy that may be implemented by the United States Food and Drug Administration if a firm refuses to undertake a requested call; Classifications of recall; When a recall will be terminated by...

  • Recalls. Nordenberg, Tamar // FDA Consumer;Oct95, Vol. 29 Issue 8, p24 

    Focuses on the factors being considered by the United States Food and Drug Administration (FDA) in recalling a product. Several incentives for a company to recall the product; Regulatory action imposed by FDA for failure to comply with its standards; Information to be sent to consumers by...

  • FDA says Iradimed recall a class I action. McCARTY, MARK // Medical Device Daily;8/13/2013, Vol. 17 Issue 155, p7 

    The article reports that the U.S. Food and Drug Administration (FDA) has announced that Iradimed's recall of the MRidium 3860+ infusion systems is a class I recall although it is limited to MRidium systems equipped with the MRidium 1145 dose error reduction system (DERS).

  • FDA to take closer look at diabetes drug. O'Connor, John // McKnight's Long-Term Care News;Apr2010, Vol. 31 Issue 4, p24 

    The article reports on the decision of the Food and Drug Administration to examine data and reports on the safety of Avandia, the diabetes drug of GlaxoSmithKline, in the U.S. in 2010.

  • Outrage of the Month: Avandia.  // Health Letter;Jul2013, Vol. 29 Issue 7, p12 

    In this article, the author expresses criticism against the U.S. Food and Drug Administration (FDA) for continuing with the prescription of the diabetes drug rosiglitazone (Avandia), that has been banned in Europe in 2010 due to its associated cardiovascular risks.

  • Mixed vote on rosiglitazone. Elliott, William T. // Neurology Alert;Sep2010 Pharmacology, p2 

    The article reports on the mixed vote issued by a U.S. Food and Drug Administration (FDA) committee regarding GlaxoSmithKline's rosiglitazone drug.

  • Mixed vote on rosiglitazone.  // OB/GYN Clinical Alert;Sep2010 Pharmacology, p2 

    The article reports the mixed decisions of the U.S. Food and Drug Administration (FDA) on the withdrawal of the diabetes drug rosiglitazone by GlaxoSmithKline.

  • WEEK IN WASHINGTON.  // BioWorld Insight;9/27/2010, Vol. 18 Issue 39, p6 

    The article reports on the decision of U.S. Food and Drug Administration that GlaxoSmithKline's diabetes drug Avandia or rosiglitazone will stay on the market, but under a tight restricted access program.

  • Panel Says Avandia Should Stay.  // Chain Drug Review;8/30/2010, Vol. 32 Issue 14, p30 

    The article reports on the decision of the U.S. Food and Drug Administration (FDA) to continue the marketing of the antidiabetic drug Avadia from GlaxoSmithKline despite evidence that the drug increases the risk of heart attack.

Share

Read the Article

Courtesy of VIRGINIA BEACH PUBLIC LIBRARY AND SYSTEM

Sorry, but this item is not currently available from your library.

Try another library?
Sign out of this library

Other Topics